


Remdesivir

Cat. No.:	HY-104077		
CAS No.:	1809249-37-3		
Molecular Formula:	C ₂₇ H ₃₅ N ₆ O ₈ P		
Molecular Weight:	602.58		
Target:	DNA/RNA Synthesis; SARS-CoV		
Pathway:	Cell Cycle/DNA Damage; Anti-infection		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (165.95 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent Concentration	Mass			
			1 mg	5 mg	10 mg	
			1 mM	1.6595 mL	8.2977 mL	16.5953 mL
			5 mM	0.3319 mL	1.6595 mL	3.3191 mL
10 mM	0.1660 mL	0.8298 mL	1.6595 mL			
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (4.15 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.17 mg/mL (3.60 mM); Clear solution					
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.17 mg/mL (3.60 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Remdesivir (GS-5734), a nucleoside analogue with effective antiviral activity, has EC ₅₀ s of 3.3 μM, 4.7 μM, 32 μM, 3.7 μM and 9.2 μM for SARS-CoV-2 and its variants alpha, beta, gamma and delta, respectively. Remdesivir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro ^{[1][2][3]} .
IC ₅₀ & Target	EC ₅₀ : 30 nM (murine hepatitis virus, delayed brain tumor cell), 74 nM (SARS-CoV, HAE cell), 74 nM (MERS-CoV, HAE cell) ^[1] EC ₅₀ : 3.3 μM (SARS-CoV-2), 4.7 μM (SARS-CoV-2 alpha), 32 μM (SARS-CoV-2 beta), 3.7 μM (SARS-CoV-2 gamma) and 9.2 μM (SARS-CoV-2 delta) ^[3]

In Vitro

Remdesivir (GS-5734) inhibits murine hepatitis virus (MHV) with an EC₅₀ of 30 nM, and blocks SARS-CoV and MERS-CoV in HAE cells with EC₅₀s of both 74 nM in HAE cells after treatment for 24 h^[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.

CUSTOMER VALIDATION

- N Engl J Med. 2022 Dec 7.
- Nature. 2021 May;593(7859):418-423
- Nature. 2020 Jun;582(7813):561-565.
- Science. 2021 Nov 26;374(6571):1099-1106.
- Science. 2020 Jun 26;368(6498):1499-1504.

See more customer validations on www.MedChemExpress.com

REFERENCES

- [1]. Hu H, et al. Optimization of the Prodrug Moiety of Remdesivir to Improve Lung Exposure/Selectivity and Enhance Anti-SARS-CoV-2 Activity. J Med Chem. 2022 Sep 22;65(18):12044-12054.
- [2]. Agostini ML, et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. MBio. 2018 Mar 6;9(2). pii: e00221-18.
- [3]. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA